Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of ZGGS18 Plus ZG005 in Advanced Solid Tumors
CTR20251130Phase 2Active
- Sponsor
- Zelgen
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ZGGS18 in Nonhematologic neoplasms, Cervical Cancer (CC), hepatocellular carcinoma (HCC), neuroendocrine carcinoma (NEC), non-small cell lung cancer (NSCLC), sponsored by Zelgen. Started May 2025; status: active.
02
Drugs
ZGGS18
03
Conditions
Nonhematologic neoplasmsCervical Cancer (CC)hepatocellular carcinoma (HCC)neuroendocrine carcinoma (NEC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251130.